Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.
You may also be interested in...
GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says
Entereg NDA has Feb. 10 user fee date for gastrointestinal recovery after bowel resection surgery.
GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says
Entereg NDA has Feb. 10 user fee date for gastrointestinal recovery after bowel resection surgery.
GSK/Adolor Entereg “Approvable” Pending CV Risk Data
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.